Other
Chorioamnionitis
11
Pipeline Programs↗
0
Active Trials↗
3
Companies Involved↗
Chorioamnionitis is an emerging landscape with 11 programs across 3 companies. The most active players are Novartis, Azurity Pharmaceuticals, Boehringer Ingelheim. 3 therapies are approved with 6 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 21
Phase 36
Analysis
Trial Status
6
clinical trials
Completed4 · 67%
Terminated1 · 17%
Withdrawn1 · 17%
Clinical Trials
Trial Activity
6 trials
Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00021671·3,720 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)